Goldman Sachs Group Inc Aveo Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	BUY	$8.48 - $14.97 $4.96 Million - $8.75 Million	584,788 Added 1010.62%	642,652 $9.61 Million
Q4 2022 Feb 13, 2023	BUY	$8.48 - $14.97 $4.96 Million - $8.75 Million	584,788 Added 1010.62%	642,652 $9.61 Million
Q3 2022 May 14, 2024	BUY	$6.61 - $8.72 $243,228 - $320,869	36,797 Added 174.67%	57,864 $476,000
Q3 2022 Nov 10, 2022	BUY	$6.61 - $8.72 $243,228 - $320,869	36,797 Added 174.67%	57,864 $476,000
Q2 2022 May 14, 2024	BUY	$3.51 - $6.67 $73,945 - $140,516	21,067 New	21,067 $138,000
Q2 2022 Aug 15, 2022	BUY	$3.51 - $6.67 $20,670 - $39,279	5,889 Added 38.8%	21,067 $138,000
Q1 2022 May 16, 2022	SELL	$3.15 - $6.01 $765,229 - $1.46 Million	-242,930 Reduced 94.12%	15,178 $85,000
Q4 2021 Feb 14, 2022	SELL	$4.69 - $7.4 $110,491 - $174,336	-23,559 Reduced 8.36%	258,108 $1.21 Million
Q3 2021 Nov 10, 2021	BUY	$5.12 - $6.89 $1.44 Million - $1.94 Million	281,667 New	281,667 $1.74 Million

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.